期刊文献+

甲巯咪唑致肝损害与黄素单加氧酶3 E308G位点基因多态性的相关性研究 被引量:4

Relationship between the Flavin-Containing Monooxygenase 3 Gene Polymorphisms and the Liver Injury Caused by Methimazole
原文传递
导出
摘要 目的 探讨黄素单加氧酶3(flavin-containing monooxygenase,FMO3)E308G位点基因多态性与甲巯咪唑(methimazole,MMI)致山东地区汉族Graves病(GD)患者肝损害的相关性。方法 研究对象选自2011年3月至2012年4月到本院内分泌科就诊、住院的Graves病患者(GD组)105例,分为2个亚组:甲巯咪唑治疗后肝损害组(肝损害组)和甲巯咪唑治疗前后肝功正常组(肝功正常组)。记录患者临床资料,收集其外周非抗凝静脉血血凝块,提取基因组DNA,应用聚合酶链反应-限制性片段长度多态性技术(PCR-RFLP)测定黄素单加氧酶3基因E308G位点基因型,计算两组的基因型和等位基因频率。结果 黄素单加氧酶3基因E308G位点的AG+GG基因型和G等位基因频率在肝损害组与肝功正常组分布差异有统计学意义(χ2=7.744,P=0.005;χ2=4.850,P=0.028)。Logistic回归分析结果显示,黄素单加氧酶3基因E308G位点G等位基因与甲巯咪唑致肝损害的发生相关,OR值为3.371,95%CI为1.357~8.379,P〈0.05。结论 黄素单加氧酶3基因E308G位点多态性可能与山东地区汉族人群GD患者甲巯咪唑致肝损害相关。 OBJECTIVE To explore the relationship between the flavin-containing monooxygenase 3 gene polymorphisms and the liver injury caused by methimazole in the Chinese Han patients with GD in Shandong area. METHODS One hundred and five Patients with GD including 65 patients without liver injury before and after using MMI( the normal liver function group) and 40 patients with liver injury caused by MMI (the MMI-induced liver injury group)were studied. The genotype and allele frequencies were assayed by polymer- ase chain reaction-restriction fragment length polymorphism (PCR-RFLP). RESULTS Significant differences in genotype frequencies and allele frequencies were observed in FMO3 E308G between the MMI-induced liver injury group and the normal liver function group(χ2 = 7. 744 ,P = 0. 005 ;χ2 = 4. 850,P = 0. 028 ) . The G allele of FMO3 is associated with the happening of liver injury caused by MMI accord to logistic regression results. CONCLUSION The polymorphism of FMO3 gene might be related to MMI-induced liver injury.
出处 《中国药学杂志》 CAS CSCD 北大核心 2014年第15期1338-1341,共4页 Chinese Pharmaceutical Journal
关键词 甲巯咪唑 黄素单加氧酶3基因 GRAVES病 肝损害 methimazole FMO3gene Graves disease liver injury
  • 相关文献

参考文献1

二级参考文献10

  • 1Liaw YF, Huang MJ, Fan KD, et al. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. Ann Intern Med,1993,118:424-428.
  • 2Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol,1990,11:272-276.
  • 3Williams KV, Nayak S, Becker D, et al. Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J Clin Endocrinol Metab,1997,82:1727-1733.
  • 4Cooper DS. Treatment of thyrotoxicosis. In: Braverman LE, Utiger RD. eds. Werner and Ingbar′s the thyroid. 7th ed. Philadelphia: Lippincott-Raven, 1996.713-734.
  • 5Huang MJ, Li KL, Wei JS, et al. Sequential liver and bone biochemical changes in hyperthyroidism: prospective controlled follow-up study. Am J Gastroenterol, 1994, 89:1071-1076.
  • 6Kim HJ, Kim BH, Han YS, et al. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. Am J Gastroenterol, 2001,96:165-169.
  • 7Garty BZ, Kauli R, Ben-Ari J, et al. Hepatitis associated with propylthiouracil treatment. Drug Intell Clin Pharm, 1985,19:740-742.
  • 8Lock DR, Sthoeger ZM. Severe hepatotoxicity on beginning propylthiouracil therapy.J Clin Gastroenterol, 1997,24:267-269.
  • 9Ozenirler S, Tuncer C, Boztepe U, et al. Propylthiouracil-induced hepatic damage. Ann Pharmacother, 1996, 30:960-963.
  • 10Gurlek A, Cobankara V, Bayraktar M. Liver tests in hyperthyroidism: effect of antithyroid therapy. J Clin Gastroenterol, 1997, 24: 180-183.

共引文献21

同被引文献50

  • 1中国甲状腺疾病诊治指南——甲状腺功能亢进症[J].中华内科杂志,2007,46(10):876-882. 被引量:845
  • 2Krueger S K, Williams D E. Mammalain flavin-containing monoo- xygenases structrue/function, genetic polymorphisms and role in drug metabolism[ J ]. Phamacol Ther, 2005, 106 (3) : 357.
  • 3Cashman J R. The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and develop- ment[ J]. Drug Discov Today, 2004,9(13) : 574.
  • 4Hemandez D, Janmohamed A. Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene cluster[J]. Pharma- eogenetics, 2004 ( 14 ) : 117.
  • 5Janmohamed A, Hernandez D, Phillips I R, et al. Cell-, tis- sue-, sex- and developmental stage-specific expression of mouseflavin-containing monooxygenases(FMOs) [J]. Biochem Pharma- col, 2004, 68(1 ):73.
  • 6Koukouritaki S B, Simpson P, Yeung C K, et al. Human hepatic flavin-containing monooxygenases 1 ( FMOI ) and 3 ( FMO3 ) evelopmental expression [ J ]. Pediatr Res, 2002, 51 (2) :236.
  • 7Cherrington N J, Cao Y, Cherrington J W, et al. Physiological factors affecting protein expression of flavin-containing monooxy- genases 1,3 and 5[J]. Xenobiotiea, 1998, 28(7):673.
  • 8Zhang J, Cashm an J R. Quantitative analysis of FMO gene mR- NA levels in hum an tissues[ J]. Drug Metab Dispos, 2006, 34 (1):19.
  • 9Mwenifumbo J C, Tyndale R F. Molecular genetics of nicotine metabolism[ J ]. Handb Exp Pharmacol, 2009 (192) :235.
  • 10Byrd G D, Chang K M, Greene J M, et al. Evidence for urinary excretion of glueuronide conjugates of nicotine, cotinine, and trans-30-hydroxyeotinine in smokers [ J 1 . Drug Metab Dispos, 1992, 20 : 192.

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部